LY 2795050

Drug Profile

LY 2795050

Alternative Names: 11C-LY2795050; LY2795050

Latest Information Update: 19 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; New York University School of Medicine; Yale University
  • Class Imaging agents
  • Mechanism of Action Opioid kappa receptor antagonists; Positron-emission tomography enhancers; Radiography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 01 Mar 2012 Clinical trials in Diagnostic imaging in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top